The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | First-in-human Phase I study of JNJ-5322, a novel trispecific antibody, in R/R myeloma
Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, shares promising results from the first-in-human Phase I study of JNJ-5322 (JNJ-79635322), a novel trispecific antibody, in patients with triple-class-exposed relapsed/refractory (R/R) multiple myeloma. Dr Lee highlights the encouraging safety profile and efficacy of this agent, noting that this may reflect a paradigm shift in the treatment of multiple myeloma. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
